{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:56:54Z","timestamp":1770137814332,"version":"3.49.0"},"reference-count":74,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/00257"],"award-info":[{"award-number":["PI17\/00257"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0009\/0030"],"award-info":[{"award-number":["RD16\/0009\/0030"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. However, this strategy only partially covered the DKD progression. Thus, new strategies for reno-cardiovascular protection in type 2 diabetic patients are urgently needed. In the last few years, hypoglycaemic drugs, such as sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, demonstrated a cardioprotective effect, mainly in terms of decreasing hospitalization for heart failure and cardiovascular death in type 2 diabetic patients. In addition, these drugs also demonstrated a clear renoprotective effect by delaying DKD progression and decreasing albuminuria. Another hypoglycaemic drug class, dipeptidyl peptidase 4 inhibitors, has been approved for its use in patients with advanced chronic kidney disease, avoiding, in part, the need for insulinization in this group of DKD patients. Studies in diabetic and non-diabetic experimental models suggest that these drugs may exert their reno-cardiovascular protective effect by glucose and non-glucose dependent mechanisms. This review focuses on newly demonstrated strategies that have shown reno-cardiovascular benefits in type 2 diabetes and that may change diabetes management algorithms.<\/jats:p>","DOI":"10.3390\/jcm8060864","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T11:24:45Z","timestamp":1560770685000},"page":"864","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes"],"prefix":"10.3390","volume":"8","author":[{"given":"Clara","family":"Garc\u00eda-Carro","sequence":"first","affiliation":[{"name":"Nephrology Research Group, Vall d\u2019Hebron Research Institute (VHIR), Nephrology Department, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1926-0147","authenticated-orcid":false,"given":"Ander","family":"Vergara","sequence":"additional","affiliation":[{"name":"Nephrology Research Group, Vall d\u2019Hebron Research Institute (VHIR), Nephrology Department, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Agraz","sequence":"additional","affiliation":[{"name":"Nephrology Research Group, Vall d\u2019Hebron Research Institute (VHIR), Nephrology Department, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN), Instituto Carlos IIIFEDER, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2518-7847","authenticated-orcid":false,"given":"Conxita","family":"Jacobs-Cach\u00e1","sequence":"additional","affiliation":[{"name":"Nephrology Research Group, Vall d\u2019Hebron Research Institute (VHIR), Nephrology Department, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN), Instituto Carlos IIIFEDER, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Espinel","sequence":"additional","affiliation":[{"name":"Nephrology Research Group, Vall d\u2019Hebron Research Institute (VHIR), Nephrology Department, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN), Instituto Carlos IIIFEDER, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2054-653X","authenticated-orcid":false,"given":"Daniel","family":"Seron","sequence":"additional","affiliation":[{"name":"Nephrology Research Group, Vall d\u2019Hebron Research Institute (VHIR), Nephrology Department, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN), Instituto Carlos IIIFEDER, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Mar\u00eda","family":"Soler","sequence":"additional","affiliation":[{"name":"Nephrology Research Group, Vall d\u2019Hebron Research Institute (VHIR), Nephrology Department, Hospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Red de Investigaci\u00f3n Renal (REDINREN), Instituto Carlos IIIFEDER, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Guideline Development Group, Bilo, H., Coentrao, L., Couchoud, C., Covic, A., De Sutter, J., Drechsler, C., Gnudi, L., Goldsmith, D., and Heaf, J. (2015). Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR < 45 mL\/min). Nephrol. Dial. Transplant., 30, 1\u2013142.","DOI":"10.1093\/ndt\/gfv100"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3390\/jcm4061171","article-title":"Endothelin Blockade in Diabetic Kidney Disease","volume":"4","author":"Anguiano","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_8","first-page":"361","article-title":"New Pharmacologic Agents for Diabetes Treatment","volume":"113","author":"Malham","year":"2016","journal-title":"Mo Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/01.CIR.100.10.1134","article-title":"Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association","volume":"100","author":"Grundy","year":"1999","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1042\/cs0900189","article-title":"Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes","volume":"90","author":"Miller","year":"1996","journal-title":"Clin. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Heart Outcomes Prevention Evaluation Study Investigators, Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., and Dagenais, G. (2000). Effects of an Angiotensin-Converting\u2013Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N. Engl. J. Med., 342, 145\u2013153.","DOI":"10.1056\/NEJM200001203420301"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.fjc.0000245405.41317.60","article-title":"Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction","volume":"48","author":"Matsusaka","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"CONSENSUS Trial Study Group (1987). Effects of Enalapril on Mortality in Severe Congestive Heart Failure. N. Engl. J. Med., 316, 1429\u20131435.","DOI":"10.1056\/NEJM198706043162301"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"SOLVD Investigators, Yusuf, S., Pitt, B., Davis, C.E., Hood, W.B., and Cohn, J.N. (1991). Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. N. Engl. J. Med., 325, 293\u2013302.","DOI":"10.1056\/NEJM199108013250501"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14656566.2018.1551362","article-title":"Preventing and treating kidney disease in patients with type 2 diabetes","volume":"20","author":"Delanaye","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zoccali, C., Blankestijn, P.J., Bruchfeld, A., Capasso, G., Fliser, D., Fouque, D., Goumenos, D., Ketteler, M., Massy, Z., and Rychl\u0131k, I. (2019). Children of a lesser god: Exclusion of chronic kidney disease patients from clinical trials. Nephrol. Dial. Transplant.","DOI":"10.1093\/ndt\/gfz023"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/ki.2010.511","article-title":"SGLT2 inhibitors: Molecular design and potential differences in effect","volume":"79","author":"Isaji","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.14740\/jocmr2976w","article-title":"Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients with Type 2 Diabetes","volume":"9","author":"Bashier","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., Edwards, R., Agarwal, R., Bakris, G., and Bull, S. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1811744"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients with Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Haring","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3389\/fendo.2018.00584","article-title":"Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1","volume":"9","author":"Paternoster","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised control","volume":"4","author":"Guja","year":"2016","journal-title":"Lancet. Diabetes Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): A 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet. Diabetes Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/dom.13666","article-title":"Superior efficacy of insulin degludec\/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes","volume":"21","author":"Billings","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12929-017-0371-7","article-title":"Distribution of glucose transporters in renal diseases","volume":"24","author":"Szablewski","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12551-015-0186-2","article-title":"Glucose transporters: Physiological and pathological roles","volume":"8","author":"Navale","year":"2016","journal-title":"Biophys. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MNH.0b013e32832f5775","article-title":"The regulation of proximal tubular salt transport in hypertension: An update","volume":"18","author":"Wang","year":"2009","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","article-title":"High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection","volume":"8","author":"Umino","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"140091","DOI":"10.1098\/rsob.140091","article-title":"Live imaging of GLUT2 glucose-dependent trafficking and its inhibition in polarized epithelial cysts","volume":"4","author":"Cohen","year":"2014","journal-title":"Open Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1681\/ASN.2017040371","article-title":"Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy","volume":"29","author":"Hinden","year":"2018","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fphys.2019.00271","article-title":"Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys","volume":"10","author":"Chung","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"F1647","DOI":"10.1152\/ajprenal.00082.2009","article-title":"Regulation of Na+\/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells","volume":"297","author":"Malnic","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1152\/ajprenal.00394.2015","article-title":"The physiological role of glucagon-like peptide-1 in the regulation of renal function","volume":"310","author":"Farah","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/dme.13618","article-title":"Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure","volume":"35","author":"Packer","year":"2018","journal-title":"Diabet. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11154-014-9287-7","article-title":"Effects of GLP-1 in the Kidney","volume":"15","author":"Skov","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy","volume":"292","author":"Wang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Panchapakesan, U., Pegg, K., Gross, S., Komala, M.G., Mudaliar, H., Forbes, J., Pollock, C., and Mather, A. (2013). Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells\u2014Renoprotection in Diabetic Nephropathy?. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054442"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00210-018-1544-y","article-title":"Empagliflozin, SGLT2inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: Potential role of klotho expression","volume":"391","author":"Abbas","year":"2018","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor\u2013dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wang, C., Li, L., Liu, S., Liao, G., Li, L., Chen, Y., Cheng, J., Lu, Y., and Liu, J. (2018). GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193473"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1507\/endocrj.EJ11-0025","article-title":"The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis","volume":"58","author":"Ito","year":"2011","journal-title":"Endocr. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13300-013-0029-8","article-title":"Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis","volume":"4","author":"Ito","year":"2013","journal-title":"Diabetes Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/14656566.2013.761690","article-title":"The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis","volume":"14","author":"Fujii","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1053\/j.ajkd.2012.11.043","article-title":"Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: A 54-week randomized trial","volume":"61","author":"Corry","year":"2013","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.2337\/dc14-1684","article-title":"Treatment with the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients with Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1","volume":"38","author":"Laakso","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_65","first-page":"dc141850","article-title":"Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial","volume":"38","author":"Udell","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 Inhibitors and the Diabetic Kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfy407","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA","volume":"34","author":"Sarafidis","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Petrie","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchf.2018.11.013","article-title":"Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists","volume":"7","author":"Vardeny","year":"2019","journal-title":"JACC Heart Fail."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/6\/864\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:59:01Z","timestamp":1760187541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/6\/864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":74,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["jcm8060864"],"URL":"https:\/\/doi.org\/10.3390\/jcm8060864","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]}}}